4//SEC Filing
Hughes-Wilson Alexandra 4
Accession 0000950170-24-106968
CIK 0001719714other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 8:46 PM ET
Size
11.6 KB
Accession
0000950170-24-106968
Insider Transaction Report
Form 4
Hughes-Wilson Alexandra
See Remarks
Transactions
- Sale
American Depositary Shares representing Ordinary Shares
2024-09-12$4.47/sh−7,769$34,748→ 190,816 total - Sale
American Depositary Shares representing Ordinary Shares
2024-09-12$4.47/sh−40,029$179,038→ 150,787 total - Sale
American Depositary Shares representing Ordinary Shares
2024-09-13$4.22/sh−16,304$68,819→ 134,483 total - Sale
American Depositary Shares representing Ordinary Shares
2024-09-13$4.22/sh−84,008$354,598→ 50,475 total
Footnotes (6)
- [F1]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
- [F2]Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive.
- [F5]The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024.
- [F6]The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3.
Documents
Issuer
Mereo BioPharma Group plc
CIK 0001719714
Entity typeother
Related Parties
1- filerCIK 0002005875
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 8:46 PM ET
- Size
- 11.6 KB